Tumor promoters are non-mutagenic chemicals which increase the probability of cancer by accelerating the clonal expansion of cells transformed during tumor initiation. Phenobarbital (PB) is an antiepileptic drug which promotes hepatocarcinogenesis in rodents when administered subsequent to an initiating carcinogen like diethylnitrosamine (DEN). Here we have investigated the prevalence and patterns of mutations in two genes, Haras and b-catenin, both known mutational targets in mouse hepatocarcinogenesis. Liver tumors were generated by a single administration of DEN to 6 week old mice followed by feeding of PB (0.05%) containing or control diet for 39 weeks. Mutations at Ha-ras codon 61 were screened by allele-speci®c oligonucleotide hybridization; b-catenin mutations were detected by direct sequencing of PCR products spanning exon 2. In tumors from mice treated with DEN alone, the prevalence of Ha-ras mutations was *30% (6/20), while no b-catenin mutations (0/13) were detectable in tumors of this treatment group. By contrast, Ha-ras mutations were undetectable in tumors from mice treated with DEN/PB (0/32), while *80% (37/46) of tumors from this group showed b-catenin mutations. These results demonstrate that PB strongly aects the prevalence of mutations in the two cancer-related genes, presumably by positive and negative selection for cells harboring the respective mutation. Oncogene (2001) 20, 7812 ± 7816 
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Keywords: b-catenin; Ha-ras; mouse hepatocarcinogenesis; phenobarbital; tumor promotion Phenobarbital (PB) is a model tumor promoter which enhances hepatocarcinogenesis in rodents if administered subsequent to initiation by a liver carcinogen such as N-nitrosodiethylamine (DEN). DEN-induced mouse liver tumors frequently harbor point mutations in ras genes, particularly at codon 61 of Ha-ras (e.g. see Buchmann et al., 1991; Bauer-Hofmann et al., 1992) . Ras proteins play an important role in cellular transduction pathways that mediate signals from transmembrane receptors into the nucleus. Activating mutations in ras lead to expression of a transforming Ras oncoprotein locked in a constitutively active GTP-complexed form (for a review see Marshall and Nigg, 1998) . A second gene often found to be mutated in both rodent and human liver tumors is b-catenin which codes for a protein associated with the intracellular domains of E-cadherin, a component of the adherens junction (for recent reviews see Willert and Nusse, 1998; Morin, 1999) . b-Catenin is also essential in the Wnt/Wingless signaling pathway and mediates nuclear responses to Wnt signals by interacting with T-cell factor (TCF, also known as lymphocyte enhancer-binding factor/LEF) transcription factors (Willert and Nusse, 1998; Morin, 1999) . b-Catenin levels are negatively regulated by phosphorylation of particular serin/threonin residues at the NH 2 -terminal region mediated by glycogen synthase kinase 3b (GSK3b). Phosphorylation by GSK3b is catalyzed by a molecular complex including, amongst others, axin1 and the adenomatous polyposis coli (APC) protein and targets b-catenin for ubiquitin/proteasome-mediated degradation (Willert and Nusse, 1998; Morin, 1999) . Inactivation of APC or mutation of b-catenin leads to increased intracellular concentration of b-catenin, turning the protein into a potentially transforming form (Morin, 1999) . We have now investigated mouse liver tumors promoted by PB treatment for the presence of mutations in Ha-ras and b-catenin to obtain some insight into the molecular mechanisms responsible for selection of transformed hepatocytes by the tumor promoter during the promotional phase of hepatocarcinogenesis.
The liver tumors used in the present study were from a previously performed experiment with connexin32 (Cx32) wildtype and knockout mice (C57BL/ 129Sv x C3H/He) which was aimed to investigate the role of Cx32 in tumor promotion by PB . In this experiment, PB was found to signi®cantly promote hepatocarcinogenesis in Cx32-wildtype mice . Liver tumors from Cx32-wildtype mice were now screened for the presence of mutations in Ha-ras codon 61 by allele-speci®c oligonucleotide hybridization as described recently (Buchmann et al., 1991; Bauer-Hofmann et al., 1992) , and b-catenin mutations were analysed by sequencing of exon 2 which corresponds to human exon 3 (de La Coste et al., 1998) . Typical examples of b-catenin mutation analyses are given in Figure 1 . As shown in Figure 2 , highly signi®cant dierences in the prevalence of mutations in the two genes were observed between treatment groups. In animals treated with DEN only, *30% of tumors (6/20) showed base substitutions in Ha-ras codon 61 while none out of 32 tumors from mice treated with DEN followed by PB harbored Ha-ras mutations (P50.002; Fisher's exact test). An inverse situation was observed with respect to b-catenin mutations: while no aberrations were detectable in any of 13 tumors analysed from mice treated with DEN alone, *80% (37/46) of tumors from mice treated sequentially with DEN and PB showed b-catenin exon 2 mutations (P50.0001; Fisher's exact test). The positions and types of mutations found in Ha-ras codon 61 and exon 2 of the b-catenin gene are presented in Table 1 . Mutations in the b-catenin gene were localized at codons 32, 33, 37 and 41, all of which aect either directly or indirectly GSK3b-mediated phosphorylation and turnover of the protein.
The most prominent types of base substitutions in both Ha-ras and b-catenin were transitions from A or T to G or C, respectively; additional types of mutations occurred at low frequency (Table 1) . The signi®cant dierences in the prevalence of Ha-ras and b-catenin mutations in liver tumors from mice treated with or without PB as a tumor promoter suggest that the barbiturate, whichs lacks mutational activity by itself, selected positively for b-catenin-mutated hepatoma cells during the promotional phase of carcinogenesis, whereas the growth of ras-mutated cells appeared to be suppressed. Our data on PB-mediated selection for a distinct population of initiated cells is in agreement with previous ®ndings by other groups. The phenotype of enzyme-altered foci in rat liver may vary depending on whether the animals were treated with a promoting agent or not and also with the type of promoter used (e.g. see Grasl-Kraupp et al., 1990; Dragan and Pitot, 1992) . It was therefore suggested that subpopulations of initiated cells containing dierent mutations will be able to grow selectively under the permissive conditions established by a tumor promoter of a certain class (Dragan and Pitot, 1992 ). PB appears to exert its growth-promoting eects predominantly on eosinophilic-clear cell foci while the peroxisome proliferator nafenopin, for example, stimulates the clonal outgrowth of diusely basophilic populations (Grasl-Kraupp et al., 1990) . Most of the lesions in PB-treated mice of the present study were of an eosinophilic-clear cell phenotype (data not shown). Since 80% of tumors in this group harbored b-catenin mutations, it is tempting to Figure 1 Examples of b-catenin mutations in mouse liver tumors. DNA isolated from larger liver tumors or tumor tissue samples taken from glucose-6-phosphatase stained liver sections by use of punching cannuli (Buchmann et al., 1991) were used for PCR ampli®cation of a 1473 bp fragment (isolated DNA) or a 297 bp fragment (tissue samples), both containing exon 2 of the b-catenin gene. Primers for ampli®cation of the 1473 bp b-catenin fragment (forward: 5'-AGCTCAGCGCAGAGCTGCTG-3'; reverse: 5'-CCTTCCTGATGGAGCAGGAGA-3') were designed to span the entire region of the gene previously shown to contain deletions of varying length in liver tumors (de La Coste et al., 1998; Devereux et al., 1999) . No deletions, however, were detected in the panel of tumor samples analysed in the present study. For ampli®cation of the 297 bp b-catenin fragment we used the sequencing primers described below. Point mutations at the known hotspots in exon 2 of the b-catenin gene were analysed by sequencing of both strands of the PCR products using the ABI Prism BigDye cycle sequencing kit and the ABI Prism 310 sequence analyzer (PE Applied Biosystems, Weiterstadt, Germany) according to the manufacturer's protocol. The sequencing primers were 5'-CAGGTAGCATTTTCAGTTCAC-3' and 5'-GCTAGCTTCCAAACACAAATG-3', respectively (modi®ed after de La Coste et al., 1998) . Each mutation detected was con®rmed by at least one independent PCR/mutation analysis and, whenever possible, veri®ed by analysis of appropriate restriction fragment length polymorphisms (data not shown) Figure 2 Prevalence of Ha-ras and b-catenin mutations in mouse liver tumors. Tumors had been induced in male mice by a single i.p. injection of DEN (90 mg/g body weight) at 6 weeks of age. After a treatment-free interval of 3 weeks, groups of animals were either kept on a standard diet (7PB) or on a diet containing 0.05% PB (+PB) for 39 weeks (for further details see Moennikes et al., 2000) . For mutation spectra see Table 1 speculate about a link between this genetic alteration and the observed phenotype of tumors.
What might be the nature of the dierential eects of PB on ras-and b-catenin-mutated hepatocytes? Ras-mutated tumors were absent in DEN/PB-treated mice. We could recently show that the activated ras oncogene mediates suppression of apoptosis of transformed mouse hepatocytes (Frey et al., 2000) . Since suppression of apoptosis is also a hallmark of tumor promoters like PB (Schulte-Hermann et al., 1995) , the barbiturate might simply neutralize a selective pressure otherwise mediated by the Ras oncoprotein. Whether additional, more direct negative eects of PB on Ha-ras mutated hepatocytes exist remains to be elucidated. Tumors harboring b-catenin mutations were promoted by PB. Mutation of bcatenin may lead to increased intracellular levels and activation as a transcription factor (Willert and Nusse, 1998; Morin, 1999) . Among the known target genes transcriptionally activated by b-catenin/(LEF/ TCF) are oncogenes like cyclin D1 and c-myc (Morin, 1999) , which are positive regulators in the cell cycle. We have therefore investigated the intracellular localization of b-catenin and the levels of cyclin D1 and c-myc proteins in a subset of liver tumors from mice of the two treatment groups. Immunohistochemical staining for b-catenin demonstrated a preferential localization of the protein at the cell membrane, both in the normal and tumor tissues, with no indication of nuclear accumulation, irrespective of treatment group (for representative examples see Figure 3a ,b). Lack of nuclear b-catenin staining in mouse liver tumors has also been reported in a previous study by Devereux et al. (1999) , whereas Ogawa et al. (1999) detected some nuclear b-catenin accumulation in a small fraction of cells in hepatocarcinoma but rarely in hepatocellular adenoma. The cellular concentrations of b-catenin and cmyc proteins were unchanged or slightly increased in tumor tissues in comparison to normal liver as shown by Western blot analysis, whereas cyclin D1 protein levels were strongly elevated in liver tumors ( Figure  3c ). Expression of all three proteins did not signi®cantly dier between b-catenin-mutated and bcatenin-wild-type tumors and was unaected by PBtreatment of mice. These results argue against the hypothesis that PB may select for b-catenin-mutated hepatocytes by interfering with b-catenin/(LEF/TCF)-dependent transcriptional programs.
In addition to its role in signaling, b-catenin is involved in cell adhesion (Willert and Nusse, 1998; Morin, 1999) . At the cell membrane, b-catenin binds to cadherins and links these molecules via a-catenin to the actin cytosceleton. Cadherins represent cell ± cell adhesion molecules which are essential for the establishment of epithelial cell shape and maintenance of the dierentiated epithelial cell type. Potentially, PB might aect processes at the cell membrane relevant for tumor promotion. Many tumor promoters, including PB, block intercellular gap junctional communication (for a review see Yamasaki and Naus, 1996) and we could recently demonstrate that functional Cx32, which is the major gap junctional protein in liver, is required for tumor promotion by PB . Although, to our knowledge, nothing is known about a physical interaction between molecules of the cell adhesion complex and Cx32, a cross talk between cadherin/b-catenin-and Cx32-triggered signal cascades may well exist. About 80% of liver tumors from PBtreated Cx32-wildtype mice showed decreased or negative expression of Cx32 and about the same percentage harbored mutations in b-catenin (this study), while the majority of tumors from mice treated with DEN alone showed unchanged or even slightly enhanced staining for Cx32 and apparently lacked b-catenin mutations (this study). Under the assumption of a causal relationship, a scenario could be envisaged in which PB selects by down-regulation of Cx32 for transformed hepatocytes harboring b-catenin mutations. Alternatively, mutation of b-catenin, seen in tumors from PB-promoted mice, could lead to lowered expression of Cx32 which would be associated with a decrease in gap junctional intercellular communication and accelerated growth, the hallmark of tumor promotion. Screenings for additional types of Ha-ras codon 61 mutations (see Buchmann et al., 1991) were negative. c Previously described deletions in the b-catenin gene in liver tumors (de La Coste et al., 1998; Devereux et al., 1999) were not observed in the panel of tumor samples analysed in the present study
